Tirosint®-Sol (levothyroxine sodium) – New Formulation Approval
December 15, 2016 – The FDA approved Institut Biochimique SA’s Tirosint-Sol (levothyroxine sodium) oral solution, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism; and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Top